News Tysabri failure in stroke a setback for Biogen Biogen’s hopes that one of its established multiple sclerosis drugs might also help stroke sufferers have been dashed.
News BioMarin starts rebuilding after its downsizing spree BioMarin has made its first M&A play under James Sabry, buying Inozyme to flesh out its enzyme replacement therapies (ERTs) for rare diseases.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
